The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2021 | Upcoming updates at ASCO GI 2021: POLO, ClarIDHy & COVID-19
Rachna T. Shroff, MD, of the University of Arizona Cancer Center, Tucson, AZ, discusses upcoming updates in gastrointestinal (GI) oncology that will be presented at this years American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, including the survival data of the POLO study (NCT02184195) in pancreatic cancer as well as the overall survival updates from the ClarIDHy study (NCT02989857) evaluating ivosidenib in cholangiocarcinoma. Dr Shroff also highlights the importance of an upcoming session evaluating the impact of the COVID-19 pandemic on the treatment of patients with GI malignancies. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
